Bendamustine Hydrochloride and Rituximab Compared With R-CVP or R-CHOP in Patients With Lymphoma

- Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma
- Completed

Study Title: Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

Teva Identifier: C18083/3064/NL/MN

ClinicalTrials.gov Identifier: NCT00877006

Study Status: Completed

Trial Condition(s): Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

Interventions: Drug: bendamustine | Drug: rituximab | Drug: vincristine | Drug: prednisone | Drug: cyclophosphamide | Drug: doxorubicin

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Click for participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age Range: 18 Years and older

Trial Duration: April 30, 2009 - March 31, 2012

Phase: Phase 3

Study Type

Interventional